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Abstract
Objectives
Chronic kidney disease (CKD) is more prevalent among women and is associated with ad-
verse cardiovascular events. Among women with symptoms and signs of ischemia enrolled
in the Women’s Ischemia Syndrome Evaluation (WISE), a relatively high mortality rate was
observed in those with no obstructive coronary artery disease. Coronary microvascular dys-
function or reduced coronary flow reserve (CFR) was a strong and independent predictor of
adverse outcomes. The objective of this analysis was to determine if renal function was as-
sociated with coronary microvascular dysfunction in women with signs and symptoms
of ischemia.
Methods
TheWISE was a multicenter, prospective, cohort study of women undergoing coronary an-
giography for suspected ischemia. Among 198 women with additional measurements of
CFR, we determined the estimated glomerular filtration rate (eGFR) with the CKD-EPI equa-
tion. We tested the association between eGFR and CFR with regression analysis.
Results
The median eGFR was 89 ml/min. The eGFR correlated with CFR (r = 0.22; P = 0.002).
This association persisted even after covariate adjustment. Each 10-unit decrease in eGFR
was associated with a 0.04-unit decrease in CFR (P = 0.04).There was a strong interaction
between eGFR and age (P = 0.006): in those60 years old, GFR was strongly correlated
with CFR (r = 0.55; P<0.0001). No significant correlation was noted in those <60 years old.
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Conclusions
Reduced renal function was significantly associated with lower CFR in women with symp-
toms and signs of ischemia. Coronary microvascular dysfunction warrants additional study
as a mechanism contributing to increased risk of cardiovascular events in CKD.
Introduction
Chronic kidney disease (CKD) is associated with adverse cardiac events and excessive cardio-
vascular (CV) mortality[1]. Traditional risk factors for atherosclerosis do not account for the
majority of risk of CV events associated with CKD [2]. Moreover, revascularization[3] or ag-
gressive treatment of CV risk factors[4,5] have had little, or at best modest, success in prevent-
ing adverse cardiac events particularly among dialysis patients, suggesting that pathogenic
mechanisms other than obstructive coronary artery disease (CAD) may contribute to excess
CV mortality in those with CKD. We previously reported that in women with symptoms or
signs of ischemia, even mild CKD is associated with coronary atherosclerosis[6]. In a cohort of
these women, coronary microvascular dysfunction (CMD), as evidenced by a decreased coro-
nary flow reserve (CFR) to adenosine, is a strong and independent predictor of adverse out-
comes over 5.4 years of follow-up[7].
CKD is associated with inflammation, and serum levels of the acute phase reactant C reac-
tive protein (CRP), interleukin-6 (IL-6), and serum amlyoid A (SAA) correlate with level of
renal function[8] and all-cause as well as cardiovascular mortality[9]. However, the association
between inflammation and microvascular disease is unclear. The pro-inflammatory cytokine
IL-6 has been shown to be elevated in obese patients with decreased CFR[10]. However, in
women with chest pain and no obstructive CAD, studies have not demonstrated an association
between CFR and IL-6 or other inflammatory markers[11].
Interestingly, CKD is associated with microvascular dysfunction in other organ systems
such as the cerebral and retinal circulation[12,13]. The role of CMD in CKD is also supported
by animal models, which show that uremic mice have reduced myocardial capillary density
[14]. In the setting of left ventricular hypertrophy, which commonly accompanies CKD, ob-
structive CAD can potentially impair vasodilatation. Pharmacological stress tests, which rely
on adenosine, have decreased sensitivity in dialysis patients compared with the general popula-
tion, suggesting the possibility of an impaired vasodilator response to adenosine in CKD [15].
We hypothesized that reduced renal function, determined by estimated glomerular filtration
rate (eGFR), would be independently associated with a reduced CFR.
Materials and Methods
TheWomen’s Ischemia Syndrome Evaluation (WISE) (clinicaltrials.gov NCT00000554), a
prospective cohort study initiated by the National Heart, Lung and Blood Institute to improve
the understanding of pathological mechanisms and diagnostic evaluation of ischemic heart dis-
ease in women, enrolled women with symptoms and signs of ischemia referred for coronary
angiography. Details of the WISE study design have been described previously[16]. Briefly, in
addition to coronary angiography, key demographic and laboratory variables were collected at
baseline including assessment of CAD risk factors, blood chemistries, lipid levels, inflammatory
markers, and functional capacity. Serum creatinine was measured using standard technique in
the clinical laboratory at each of the four sites. Creatinine clearance (ml/min) was estimated
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with use of the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation after
decreasing creatinine levels by 5%, as recommended[17] for calibration. Lipids were measured
in fasting blood plasma at the WISE lipid core laboratory (Cedars-Sinai Medical Center, Los
Angeles, CA). Qualitative and quantitative CAD measures were made at the angiographic core
laboratory masked to other clinical data[18]. Women with at least one50% diameter stenosis
were classified as having significant CAD, those with maximum stenosis20% but<50% as
minimal CAD, and women with<20% stenosis in all coronary arteries as no CAD. A CAD se-
verity score was calculated by a modified Gensini index termed the WISE CAD severity score.
All patients provided written informed consent, and the protocol was approved in accordance
with the ethical principles outlined in the 1975 Declaration of Helsinki by the institutional re-
view boards at each center (University of Florida, Gainesville, FL; University of Pittsburgh,
Pittsburgh, PA; Cedars-Sinai Medical Center, Los Angeles, CA; and Rhode Island Hospital,
Providence, RI).
Coronary reactivity testing protocol
Coronary reactivity testing was performed in a stenosis free area of the left anterior descending
coronary artery when possible, with the left circumflex artery as a secondary choice[19]. A
Doppler-tipped guidewire (0.014-inch FloWire, JOMED/Cardiometrics, Mountain View, CA,
now Volcano Corporation, San Diego, CA) was advanced through the diagnostic catheter, and
when a stable velocity signal was obtained, baseline recordings were made. Intracoronary bolus
injections of 18 mcg of adenosine (Adenocard, Fujisawa USA, Deerfield, IL), a predominantly
non–endothelium-dependent microvascular dilator, was administered into the left main coro-
nary artery. A dose of 18 mcg was chosen, since in the WISE cohort, we have previously found
that CFR measurements were identical regardless of if we used low (18 mcg) or high (36 mcg)
dose of adenosine[20]. At least 3 injections were done to assure a stable average peak blood
flow velocity was obtained, with return to baseline velocity documented before each bolus.
Pulsed-wave Doppler flow spectra were used to calculate time-averaged peak velocity (APV).
Recordings were analyzed at the WISE CFR Core Lab (University of Florida) masked to all
other data, and CFR was defined as the ratio of APV after adenosine to average baseline veloci-
ty just before adenosine. In prior WISE studies, this measure correlated closely (r = 0.87,
P<0.001) with volumetric flow[18].
Statistical analysis
There were 198 patients with measurements available for CFR and eGFR. Clinical characteris-
tics were stratified by median renal function (eGFR89 or<89 ml/min/1.73 m2) and CFR
(2.5 or<2.5). Data are presented as either mean ± standard deviation for continuous vari-
ables or n(%) for categorical variables. Skewed variables are reported as medians (IQR) and
transformed to log base 2 to satisfy the assumptions of homogeneity, linearity, and Gaussian
distribution of errors. General linear regression was applied to compute P-values for continu-
ous variables, and logistic regression for categorical variables. All P-values for baseline vari-
ables, except age, are age-adjusted. Normality of log2CFR and eGFR were tested using the
Kolmogorov-Smirnov test. Pearson’s correlation was used to check univariate correlation be-
tween log2CFR, eGFR, and demographic factors. Multivariable linear regression analysis was
conducted to identify potential predictors of CFR including history of diabetes, hypertension,
dyslipidemia, metabolic syndrome, body mass index (BMI), CAD severity score, double prod-
uct (heart rate X systolic blood pressure), hemoglobin, ever smoker, CRP, IL-6, SAA, age, cur-
rent hormone replacement therapy, and eGFR (in unit of 10). A backward selection was
employed, and covariates with P-value>0.2 were sequentially removed from the model.
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History of diabetes, hypertension, and dyslipidemia were forced into the model. All statistical
analyses were conducted using SAS 9.3 (SAS Institute, Cary, NC).
Results
Baseline characteristics
The mean age was 55±10 years, and most women were menopausal (74%) and had multiple
risk factors for CAD including hypertension (56%), hyperlipidemia (51%), metabolic syn-
drome (45%), diabetes (22%), and smoking (20%). The baseline characteristics categorized by
renal function (eGFR89 or<89 ml/min/1.73 m2) and CFR (2.5 or<2.5) are summarized
in Table 1.
Renal function and CFR
In univariate analysis, renal function, eGFR, was significantly correlated with CFR (r = 0.22,
P = 0.002), as shown in Fig 1. The association persisted even when adjusted for age, diabetes,
hypertension, dyslipidemia, double product, BMI, severity of obstructive CAD, and current
hormone replacement therapy (P = 0.0003, model R2 = 0.18). No other variables were signifi-
cant independent predictors of CFR. Results of the multivariable regression are summarized in
Table 2.
Inflammatory markers, eGFR, and CFR
When stratified by eGFR and CFR, in women with renal dysfunction, CRP, IL-6, and SAA
were higher in those with low CFR compared with those with normal CFR. However, analysis
of variance adjusted for age showed no significant differences between groups (Table 1). In the
multivariable regression model, inflammatory markers CRP, IL-6, and SAA did not contribute
significantly to the model.
Age, renal function, and CFR
When age was included in the model, eGFR remained an independent predictor of CFR
(r = 0.22, P = 0.0001) even though age and renal function showed a significant interaction
(P = 0.006). When age was dichotomized as < or 60 years, 42% of women with eGFR
<89 ml/min/1.73 m2 and 48% of those with eGFR89 ml/min/1.73 m2 who were<60
years old had a low CFR (<2.5). However, in those60 years old, 63% of those with
eGFR <89 ml/min/1.73 m2 had a low CFR compared with only 36% of those with eGFR
89 ml/min/1.73 m2. eGFR and CFR showed a linear correlation among those60 years
old (r = 0.55, P<0.0001), while there was no significant correlation in those<60 years old
(r = 0.02, P = 0.81) (Fig 2). The interaction of age and renal function persisted even when
hormone replacement therapy was included as a covariate.
Discussion
Studies examining the association of CFR with renal function have shown conflicting results. A
study of 22 non-diabetic subjects found no significant differences in CFR between individuals
with moderate to severe CKD and 10 healthy controls[21]. However, this was a relatively small
sample of mostly men (66%), and even the apparently healthy controls had an average eGFR of
76±5 ml/min/1.73 m2, which is below normal. Others have found an association between CFR
and renal function. Charytan et al. assessed CFR by positron emission tomography in 435 non-
diabetic individuals. Although baseline CFR was significantly associated with eGFR, no signifi-
cant association was found after adjusting for age and hypertension status, but on longitudinal
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follow up a decline in eGFR was a strong and independent predictor of a decrease in CFR[22].
However, Charytan et al. estimated CFR using intravenous adenosine with positron imaging,
Table 1. Baseline characteristics of the study population, categorized by glomerular filtration rate (eGFR) and coronary flow reserve (CFR).
Baseline Characteristic Total CFR<2.5 eGFR<89
(n = 54)
CFR2.5 eGFR<89
(n = 48)
CFR<2.5 eGFR89
(n = 45)
CFR2.5 eGFR89
(n = 51)
P-
Value*
CKD-EPI eGFR, Mean ± SD 85±19 67±17 74±10 101±8 100±9 <0.0001
Demographics and Medical
History
Age, years 55±10 62±10 56±9 50±9 50±8 <0.001
Post-menopausal % 74 89 77 64 65 0.86
Non-white % 18 13 15 16 27 0.14
Current HRT use % 46 36 54 47 47 0.15
SBP, mmHg 135±21 143±22 131±19 133±23 133±19 0.30
DBP, mmHg 77±11 77±10 74±12 77±8 78±12 0.79
Pulse pressure, mm Hg 59±18 66±20 56±17 56±20 55±14 0.17
Pulse, beats/min 73±12 72±11 70±13 79±11 72±11 0.81
HTN % 56 67 42 53 62 0.33
Current anti-HTN Rx % 61 70 50 62 59 0.97
Dyslipidemia % 51 62 48 53 42 0.97
Diabetes % 22 28 6 24 28 0.22
Metabolic syndrome % 45 57 39 36 46 0.17
Family history of CAD % 70 74 65 71 70 0.55
Current smoker % 20 13 19 24 26 0.94
Ever smoker % 57 63 50 53 62 0.66
DASI, medians (Q1,Q3) 14(7,25) 10(5,16) 24(11,32) 13(7,24) 12(7,25) 0.38
Laboratory Data
Total cholesterol, mg/dl 188±45 194±48 183±42 184±39 189±49 0.94
Triglycerides, mg/dl 144±140 153±115 133±105 130±94 160±209 0.98
HDL, mg/dl 51±13 52±11 50±12 52±12 51±15 0.77
LDL, mg/dl (calculated) 111±39 119±45 106±34 109±35 111±42 0.57
Hemoglobin, g/dl 13.0±1.4 13.0±1.7 13.4±1.1 12.9±1.1 12.6±1.4 0.15
Creatinine, mg/dl 0.79±0.22 0.96±0.30 0.87±0.11 0.64±0.10 0.66±0.10 <0.0001
Inﬂammatory Markers
Hs-CRP, mg/dl, medians (Q1,
Q3)
(0.15,0.88) (0.20,0.80) (011,0.63) (0.20,0.98) (0.16,0.95) 0.19
IL6, pg/ml, medians (Q1, Q3) (1.71,5.26) (1.69,5.75) (1.87,4.84) (1.82,4.65) (1.65,4.51) 0.94
SAA, mg/dl, medians (Q1,
Q3)
(0.30,0.94) (0.33, 1.20) (0.24,0.58) (0.33,0.95) (0.35,0.90) 0.73
Angiographic Data
CAD( 50% stenosis)% 18 36 17 11 14 0.08
CAD severity score, medians
(Q1, Q3)
6(5,9) 9(5,14) 5(5,8) 5(5,8) 5(5,9) 0.16
CFR, medians (Q1, Q3) 2.5(2.1,3) 2.0(1.7,2.3) 3.0(2.6,3.4) 2.2(1.9,2.3) 2.9(2.6,3.3) <0.0001
CKD-EPI = Chronic Kidney Disease Epidemiology Collaboration equation, eGFR = estimated glomerular ﬁltration rate, HRT = hormone replacement
therapy, SBP = systolic blood pressure, DBP = diastolic blood pressure, HTN = hypertension, CAD = coronary artery disease, DASI = Duke Activity
Status Index, HDL = high density lipoprotein, LDL = low density lipoprotein, Hs-CRP = high-sensitivity C-reactive protein, Q1 = 25th percentile, Q3 = 75th
percentile, IL-6 = interleukin 6, SAA = serum amyloid A. P-values represent the comparison between four GFR/CFR combination groups. P-values for all
variables except age were adjusted for age.
doi:10.1371/journal.pone.0125374.t001
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and coronary angiographic data were not available. Although overall the patients were mostly
male (74%), there were significant sex differences in the subgroups, with 51% women in the
Fig 1. Linear Regression of CFR and eGFR.Coronary flow reserve (CFR) was log transformed. Estimated glomerular filtration rate (eGFR) was
determined using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
doi:10.1371/journal.pone.0125374.g001
Table 2. Independent predictors of coronary flow reserve (CFR).
Model 1 (R2 = 0.18) Model 2 (R2 = 0.22)
β (SE) P-value (add in order) β (SE) P-value (add in order)
Age -0.05(0.04) 0.0003 0.03(0.05) 0.0003
Diabetes 0.02(0.09) 0.52 -0.004(0.09) 0.52
Hypertension -0.08(0.07) 0.31 -0.08(0.07) 0.29
Dyslipidemia -0.04(0.07) 0.52 -0.04(0.07) 0.51
HR×SBP -0.04(0.02) 0.041 -0.03(0.02) 0.037
BMI 0.008(0.005) 0.15 0.006(0.005) 0.14
CAD score -0.009(0.005) 0.06 -0.01(0.005) 0.05
Current HRT 0.13(0.06) 0.047 0.12(0.06) 0.042
eGFR 0.04(0.02) 0.040 0.01(0.02) 0.036
Interaction of eGFR and Age - - 0.05(0.02) 0.006
SE = standard error, HR = heart rate, SBP = systolic blood pressure, BMI = body mass index, CAD = coronary artery disease, HRT = hormone
replacement therapy, eGFR = glomerular ﬁltration rate ml/min/per 1.73 m2. Age and eGFR were divided by 10 and double product by 1000
for consistency.
doi:10.1371/journal.pone.0125374.t002
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severe CKD group but only 27% in mild CKD and 16% in healthy controls. Thus it is not clear
how their results apply to women, particularly those without significant obstructive CAD.
Chade et al. assessed CFR using intracoronary adenosine in 605 patients without significant
obstructive CAD[23]. Patients with eGFR60 ml/min/1.73 m2 had higher CFR compared to
those with eGFR<60 ml/min/1.73 m2. CFR was lower in women, the elderly, and those with
hypertension. Multiple logistic regression analysis adjusted for age, sex, and hypertension
showed that the association of renal function and CFR persisted. But when subjects were di-
chotomized into groups with eGFR60 and<60 ml/min/1.73 m2, there was no discernible ef-
fect of milder degrees of renal failure on CFR, particularly in women. Bezante et al. suggested
that an eGFR of<60 ml/min/1.73 m2 conferred a seven-fold higher risk of having an impaired
CFR[24], but there were only 7 women with CKD.
Our study, the only one focusing solely on women, contained the largest number of women
with coronary angiographic data, and had a prospectively defined protocol requiring that an-
giograms and CFR recordings be read by core labs masked to all other patient data. Determina-
tion of CMD was by direct coronary blood flow measurements in response to intracoronary
adenosine to measure CFR. We found that even among women with only mild renal dysfunc-
tion, CFR is linearly associated with eGFR, with each 10-unit decrease in eGFR being associated
with a 0.02-unit decrease in CFR (P = 0.004). We have previously shown in the WISE cohort
that clinical and demographic variables explain only 16% of the variance in CFR and are not in-
dependently associated with CFR. eGFR on the other hand is significantly associated with CFR,
even after controlling for multiple covariates including diabetes, hypertension, dyslipidemia
and severity of obstructive coronary artery disease.
An important confounder is that CKD is more prevalent with aging[25]. Likewise CMD is
more frequent in older individuals, particularly those60 years old[25,26]. As expected, when
age is included as a covariate in models where GFR is estimated using equations as opposed to
directly measured, the association between GFR and cardiovascular events is greatly reduced
[27]. Importantly, in our model eGFR was associated with CFR even when controlled for age,
validating the strength of the association. There was a significant interaction between age and
renal function—in those60 years old there was a strong linear correlation between eGFR and
CFR which was not present in those<60 years old. Further mechanistic studies are critical to
determine whether coronary microvascular and renal dysfunction are due to aging, per se, or
due to a common, as yet unidentified, pathological process.
A low CFR has been associated with inflammation. In discordant male twins, Vaccarino
et al. found that reduced CFR on PET scan was associated with elevated levels of inflammatory
Fig 2. Scatter plot of eGFR and Log2CFR in women (A) <60 years of age (n = 135) and (B)60 years of
age (n = 63). C oronary flow reserve (CFR) was log transformed. Estimated glomerular filtration rate (eGFR)
was determined using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
doi:10.1371/journal.pone.0125374.g002
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markers[28]. A decreased CFR has also been demonstrated in inflammatory disorders such as
rheumatoid arthritis[29] and lupus[30]. Interestingly, in our exclusively female cohort inflam-
matory markers such as CRP, IL-6, and SAA were not associated with renal function and did
not add to the ability of eGFR to predict CFR. This suggests that in women with CMD, CKD
and decreased CFR are not a consequence of inflammation. CKD is often associated with hy-
pertension and left ventricular hypertrophy (LVH). Decreased CFR has been demonstrated in
conditions accompanied by LVH such as aortic stenosis[31] and Fabry’s disease[32]. In the
WISE cohort, characterized by mild renal dysfunction and very little ventricular hypertrophy,
we have previously shown that LVH does not predict CFR.
Study limitations
Although our study showed a statistically significant relation between CFR and GFR, renal
function only explains 4% of the variance in CFR overall (r = 0.21) and 30% in those over the
age of 60 years (r = 0.55). This is at least in part because the WISE cohort included women who
were referred for coronary angiography and thus excluded those with severe renal dysfunction.
This limits generalization of results to other populations. We did not assess proteinuria at base-
line or at follow up. Recent data suggest that presence of albuminuria would better stratify
those at risk for vascular events, especially among those with milder degrees of CKD[33]. We
did not have longitudinal assessment of renal function. This is particularly relevant since some
studies have suggested that CFR correlates with changes in renal function[22]. Although our
limited numbers precluded subgroup and outcome analysis, we have previously shown that
CFR was the most important predictor of major adverse outcomes in a larger WISE cohort
with 5.4 years follow-up[7]. This also held true among the women without obstructive CAD.
The CFR significantly improved prediction of adverse outcomes over angiographic CAD sever-
ity and other risk conditions. Recent studies have suggested that CFR might predict those at
high risk of CAD events in patients with CKD[34,35].
Conclusion
Our results demonstrate that renal function estimated by eGFR is significantly associated with
CFR, and even mild decline in renal function is associated with CMD. Treatment modalities di-
rected at traditional risk factors for atherosclerosis have had little impact in reducing mortality
and morbidity in patients with CKD. CMD deserves additional study as a contributor to in-
creased cardiovascular morbidity and mortality associated with CKD. Understanding the
mechanistic basis of CMD in women with CKD has the potential to identify targets for novel
therapeutics and to improve prognosis in a high-risk cohort for whom conventional therapies
have been uniformly disappointing.
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